Seattle Genetics, Inc. today highlighted clinical data from two antibody-drug conjugate programs in development by Genentech, a member of the Roche Group that utilize Seattle Genetics' technology.
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20121211005238&newsLang=en&ndmConfigId=1000639&vnsId=41
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20121211005238&newsLang=en&ndmConfigId=1000639&vnsId=41
No comments:
Post a Comment